Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.68 |
| ▸ | CTSS | P25774 | 5/20 | 0.68 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.57 |
| ▸ | CTSB | P07858 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 4/20 | 0.53 |
| ▸ | PPARG | P37231 | 3/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12560624 | 1.00 | CTSK (0.68) | CTSKCTSSKLK5CTSBCTSL | |
| SCHEMBL7032329 | 1.00 | CTSK (0.68) | CTSKCTSSKLK5CTSBCTSL | |
| SCHEMBL7300194 | 0.92 | CTSK (0.60) | CTSKCTSSKLK5CTSBCTSL | |
| SCHEMBL23734347 | 0.92 | CTSS (0.62) | CTSKCTSSKLK5CTSBCTSL | |
| SCHEMBL23176824 | 0.90 | CTSK (0.58) | CTSKCTSSKLK5CTSBCTSL | |
| Serine SCHEMBL7732130 | 0.90 | CTSK (0.57) | CTSKCTSSKLK5CTSBCTSL | |
| SCHEMBL3881683 | 0.90 | CTSS (0.65) | CTSKCTSSKLK5CTSBCTSL | |
| SCHEMBL8062883 | 0.90 | CTSS (0.65) | CTSKCTSSKLK5CTSBCTSL | |
| SCHEMBL8696309 | 0.90 | CTSS (0.65) | CTSKCTSSKLK5CTSBCTSL | |
| SCHEMBL21883815 | 0.89 | CTSS (0.65) | CTSKCTSSKLK5CTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114269431-A | Enzyme inhibitors | 卡尔维斯塔制药有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20150266920-A1 | MACROCYCLIC KETOAMIDE IMMUNOPROTEASOME INHIBITORS | HOFFMANN-LA ROCHE INC. | 2015-09-24 | — | — | US | disclosed |
| EP-2906582-A1 | MACROCYCLIC KETOAMIDE IMMUNOPROTEASOME INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-08-19 | — | — | EP | disclosed |
| CN-104854124-A | Macrocyclic ketoamide immunoproteasome inhibitors | HOFFMANN LA ROCHE | 2015-08-19 | — | — | CN | disclosed |
| WO-2014056954-A1 | MACROCYCLIC KETOAMIDE IMMUNOPROTEASOME INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-17 | — | — | WO | disclosed |
| US-6846820-B2 | For therapy of diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PFIZER INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-20040006088-A1 | For therapy of diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PFIZER INC. | 2004-01-08 | — | — | US | disclosed |
| US-6649634-B2 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PFIZER, INC. | 2003-11-18 | — | — | US | disclosed |
| US-20020028810-A1 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | HOOVER DENNIS J (US) | 2002-03-07 | — | — | US | disclosed |
| US-6297269-B1 | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors | PFIZER INC. | 2001-10-02 | — | — | US | disclosed |
| EP-0832066-B1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER (US) | 2001-09-12 | — | — | EP | disclosed |
| CN-1178517-A | Process for reduction of carbonyl compounds | KANEKA CORP (JP) | 1998-04-08 | — | — | CN | disclosed |
| EP-0832066-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996039385-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028810-A1 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PYGL, GPR119, PYGM | CTSK 2876/4885CTSS 2125/4885KLK5 3701/4885 |
| US-20040006088-A1 | For therapy of diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PYGL, GPR119, PYGM | CTSK 3164/4885CTSS 2377/4885KLK5 3737/4885 |
| US-20150266920-A1 | MACROCYCLIC KETOAMIDE IMMUNOPROTEASOME INHIBITORS | PSMB7, PSMC2, PSMB8 | CTSK 68/4885CTSS 91/4885KLK5 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.